TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00077051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytochlor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrouridine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02937025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td
Description: Implanting the Occluder to close the left atrial appendage
Study: NCT00932984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
Study: NCT00053703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: oral risperidone 0.5mg to 6mg daily for up to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine (enrollment closed in this treatment)
Description: oral olanzapine 5-20mg per day for up to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Molindone
Description: oral molindone from 10-140mg/daily for up to 52 weeks
Study: NCT04820374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pupil's light and pupil diameter
Description: It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
Study: NCT04510688

Intervention type: DRUG
Intervention: Cabozantinib
Description: Observation of treatment with Cabozantinib

Intervention type: DRUG
Intervention: Cabozantinib
Description: Observation of treatment with Cabozantinib
Study: NCT03044886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Subjects took vitamin D or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Subjects took vitamin D or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: Subjects took vitamin D or placebo
Study: NCT03626584

Intervention type: OTHER
Intervention: 18F-NaF PET
Description: Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes

Intervention type: OTHER
Intervention: 18F-NaF PET
Description: Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
Study: NCT00703053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1203/04
Description: Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Indonesia/05/05
Description: Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Indonesia/05/05
Description: Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Indonesia/05/05
Description: Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Indonesia/05/05
Description: Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Indonesia/05/05
Description: Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
Study: NCT04452903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication skills
Description: 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
Study: NCT03208751

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise training
Description: Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis.
Study: NCT02903082

Intervention type: BIOLOGICAL
Intervention: Residue of blood further to NFS

Intervention type: BIOLOGICAL
Intervention: Residue of blood further to preoperative workup

Intervention type: BIOLOGICAL
Intervention: Bone marrow collected during a myelogram carried out for hematological pathology workup

Intervention type: BIOLOGICAL
Intervention: Bone marrow collected during myelogram routinely performed during hospitalization in ICU
Study: NCT03920722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
Study: NCT03715153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUMETANIDE (S95008) for week 0 - 26
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO for week 0 - 26
Description: Oral solution Taken twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.
Study: NCT02779738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally
Study: NCT00433342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Description: 500 mg QD oral
Study: NCT01770912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers
Description: Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
Study: NCT01708291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based stress reduction
Description: an 8 week group intervention to teach mindfulness skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: only pre and post evaluation measures
Study: NCT02176187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat® inhaler
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat® inhaler
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® metered dose inhaler
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® metered dose inhaler
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg
Study: NCT06235840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory adaptive training
Description: The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multi-domain non-adaptive control training
Description: The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
Study: NCT02798822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
Study: NCT03228069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood drawn after rabies booster vaccination
Description: Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood drawn after rabies booster vaccination
Description: Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
Study: NCT04170790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg
Description: Saxagliptin 5mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: Sildenafil 50 mg Oral Tablet
Study: NCT01200238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Study: NCT00482443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A software programme in mobile telephone
Description: Use of Mobile phone technology in maintaining Diabetes Interactive Diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Programme.
Description: Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
Study: NCT04295616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV)
Description: IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active breathing training
Description: The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active breathing training
Description: The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
Study: NCT03171727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: After TIPS procedure was performed, low molecular weight heparin was given for three days.
Study: NCT01028326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10 and DTaP
Description: A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10 and DTaP
Description: A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine, DTaP, PCV10
Description: A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
Study: NCT01903291

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: As described in the treatment arm
Study: NCT00637975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops.
Study: NCT01034332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TP-HDFL,TP-CCRT, Esophagectomy
Description: To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
Study: NCT03288103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
Study: NCT03405597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Hepatitis B vaccine
Description: Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
Study: NCT04553510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and steroid
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and placebo
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
Study: NCT00393952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/Formoterol fumarate 250/10
Description: FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/Formoterol fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250
Description: Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02975492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol sequential dose
Description: sequential dose administration of the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol daily dose
Description: daily dose administration of the treatment
Study: NCT03827772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: 30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: Nutritional supplementation, supportive management.
Study: NCT02193048

Intervention type: OTHER
Intervention: This study will evaluate a new clinical scoring system in patients receiving routine treatment
Description: Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
Study: NCT03898492

Intervention type: OTHER
Group type: OTHER
Intervention: Physical training
Description: Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
Study: NCT02000427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
Study: NCT04759261

Intervention type: OTHER
Group type: OTHER
Intervention: SMAD4 expression and methylation
Description: Effect of SMAD4 methylations on smad4 expression
Study: NCT03359525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous versus Intraarticular versus intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous versus Intraarticular versus intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous versus Intraarticular versus intravenous
Study: NCT03497806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP101
Description: Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
Study: NCT02380950

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 250 ml alcohol consumption
Description: Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510.
Study: NCT01955447

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no added plant-based ingredients to starchy meal
Description: no added plant-based ingredients to starchy meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low level plant-based ingredients added to starchy meal
Description: Low level plant-based ingredients added to starchy meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium level plant-based ingredients added to starchy meal
Description: Medium level plant-based ingredients added to starchy meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High level plant-based ingredients added to starchy meal
Description: High level plant-based ingredients added to starchy meal
Study: NCT00475722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 Healthy Eating
Description: 6 months telephone counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Mediterranean
Description: 6 months telephone counseling
Study: NCT01395251

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: prednisolone 20 mg once a day per os for 3 subsequent days
Study: NCT03128970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronizing blastocysts
Description: transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.